Compass Pathways
Our vision is a world of mental wellbeing
Our vision is a world of mental wellbeing
Compass Pathways is a biotechnology company founded in 2016 and headquartered in the United Kingdom. The company's slogan, "Our vision is a world of mental wellbeing," reflects its dedication to accelerating patient access to evidence-based innovation in mental health.
The company's first clinical development program focuses on researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. Compass Pathways aims to transform the patient experience in mental health care, demonstrating its commitment to tackling one of the most pressing issues in healthcare.
Compass Pathways' last investment of $125.00M in Post-IPO Equity came on 16 August 2023, showcasing strong investor confidence in the company's mission and potential. The investment was made by a consortium of prominent firms, including RA Capital Management, Vivo Capital, Laurion Capital, Logos Capital, Soleus Capital, TCG Crossover, Paradigm BioCapital Advisors, PFM Health Sciences, Surveyor Capital, and Armistice Capital.
Overall, Compass Pathways' innovative approach to mental health treatment, coupled with significant financial backing from reputable investors, positions it as a promising player in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $125.00M | 10 |
|
16 Aug 2023 |
| Post-IPO Debt | $30.00M | 1 |
|
05 Jul 2023 |
| Series B | $80.00M | 10 |
|
27 Apr 2020 |
| Convertible Note | Unknown | 1 |
|
01 Sep 2019 |
| Series A | £25.00M | 1 |
|
03 Oct 2018 |
No recent news or press coverage available for Compass Pathways.
We care about your data, and we'd love to use cookies make your experience better.
